Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
c-MET Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
c-MET Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
c-MET inhibitor is a targeted therapy that specifically inhibits the activity of the c-MET receptor, a protein involved in cell growth, survival, and metastasis. The mechanism of action of c-MET inhibitors involves blocking the activation of c-MET and downstream signaling pathways, thereby inhibiting tumor growth, angiogenesis, and metastasis. These inhibitors are used in the treatment of various disease indications, including lung cancer, liver cancer, gastric cancer, and colorectal cancer, where aberrant c-MET signaling is implicated in tumor progression. According to the World Health Organization (WHO), lung cancer is one of the leading causes of cancer-related deaths worldwide. In Europe, it is estimated that there were 470,000 new cases of lung cancer in 2020, with approximately 400,000 deaths. In the United States, the American Cancer Society reported that lung cancer accounted for about 11% of all new cancer cases in 2020, with around 135,000 deaths. Liver cancer is another significant indication where c-MET inhibitors show potential. According to the WHO, liver cancer is the sixth most common cancer globally, with about 905,000 new cases and 830,000 deaths reported in 2020. Gastric cancer is prevalent in Europe, with approximately 160,000 new cases reported annually, as stated by the European Society for Medical Oncology (ESMO). Colorectal cancer is a significant burden in the United States, with the National Cancer Institute estimating around 149,500 new cases and 52,980 deaths in 2020.
The growth of the c-MET inhibitor market is driven by several factors, including the increasing prevalence of cancer, advancements in molecular biology and personalized medicine, and ongoing research and development efforts. These factors contribute to a growing demand for targeted therapies like c-MET inhibitors, as they offer the potential for improved patient outcomes and enhanced treatment options. Companies such as J&J, Exelixis, Amgen, BMS, Eli Lilly, Sino Biopharm, Betta Pharma, Merck (MSD), Ipsen, Simcere, Takeda, Daiichi Sankyo, DeuterOncology, EMD Serono, Mirati, Octimet, Otsuka, Pfizer, Roche, Servier, and AbbVie cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Roche is one such company that is currently conducting a clinical trial of the drug Onartuzumab (RG3638) for the treatment of lung neoplasms.
Key Developments
Approved c-MET Inhibitor molecules
c-MET Inhibitor Pipeline Molecules
Clinical Activity and Development of c-MET Inhibitor
|
Product Name |
Total Studies |
|
Tivantinib (ARQ 197) |
50 |
|
Sitravatinib (MGCD516) |
37 |
|
Onartuzumab (RG3638) |
17 |
|
Rilotumumab (AMG 102) |
17 |
|
Ficlatuzumab (AV-299) |
12 |
|
Foretinib (GSK1363089) |
11 |
|
Merestinib (LY2801653) |
11 |
|
Bozitinib (APL-101) |
8 |
|
Golvatinib (E7050) |
8 |
|
AL2846 |
7 |
|
Glesatinib (MGCD265) |
7 |
|
Ningetinib (CT053PTSA) |
7 |
|
AMG 337 |
6 |
|
Emibetuzumab (LY2875358) |
6 |
|
Gumarontinib (SCC244) |
6 |
|
HS-10241 |
5 |
|
Envonalkib (TQ-B3139) |
5 |
|
Unecritinib (TQ-B3101) |
5 |
|
Zanzalintinib (XL092) |
5 |
|
ABN401 |
4 |
c-MET inhibitors are targeted therapies designed to inhibit the activity of the c-MET receptor, a protein involved in cell growth, survival, and metastasis. These inhibitors have shown promise as potential treatments for various types of cancers, including lung, liver, gastric, and colorectal cancers, where aberrant c-MET signaling is implicated in tumor progression. By blocking the activation of c-MET and downstream signaling pathways, c-MET inhibitors aim to inhibit tumor growth, angiogenesis, and metastasis. Additionally, they may enhance the effectiveness of other cancer therapies. Clinical trials are underway to evaluate the efficacy and safety of c-MET inhibitors in different patient populations, with the goal of improving treatment outcomes and expanding treatment options for cancer patients.
The global c-MET Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US market analysis of c-MET inhibitors indicates a promising landscape for these targeted therapies. The United States has a well-established healthcare infrastructure and a robust oncology market, making it a key region for the development and commercialization of c-MET inhibitors. The presence of a large patient population affected by various types of cancers, such as lung, liver, and gastric cancers, creates a significant market opportunity. Additionally, the US regulatory environment and favorable reimbursement policies further support market growth for c-MET inhibitors. Several growth drivers are contributing to the expansion of the c-MET inhibitor market. Firstly, the increasing prevalence of cancer in the United States, coupled with the growing understanding of the role of c-MET signaling in tumor progression, creates a strong demand for targeted therapies like c-MET inhibitors. Secondly, advancements in molecular biology and personalized medicine have enabled better patient stratification and identification of those who may benefit from c-MET inhibitors. This precision medicine approach enhances the potential for higher response rates and improved patient outcomes. Furthermore, ongoing research and development efforts in the field, including the exploration of combination therapies and novel drug formulations, are expected to drive market growth by expanding the therapeutic potential of c-MET inhibitors. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for c-MET Inhibitors. These countries are increasingly adopting c-MET Inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the c-MET Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the c-MET Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
c-MET Inhibitors drugs are used in the management of lung cancer, liver cancer, gastric cancer, and colorectal cancer, where aberrant c-MET signaling is implicated in tumor progression.
The growth of the c-MET inhibitor market is driven by several factors, including the increasing prevalence of cancer, advancements in molecular biology and personalized medicine, and ongoing research and development efforts.
The major players in this space are J&J, Exelixis, Amgen, BMS, Eli Lilly, Sino Biopharm, Betta Pharma, Merck (MSD), Ipsen, Simcere, Takeda, Daiichi Sankyo, DeuterOncology, EMD Serono, Mirati, Octimet, Otsuka, Pfizer, Roche, Servier, and AbbVie.
The c-MET inhibitor market faces significant restraints due to challenges in drug development, including limited efficacy and safety concerns associated with the inhibition of c-MET signaling pathways. Additionally, the presence of alternative treatment options and competition from other targeted therapies further restricts the growth potential of the c-MET inhibitor market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.